dr. schmid on the design and findings of the keynote-173 trial in tnbc
Published 5 years ago • 232 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
1:46
dr. schmid discusses the findings of impassion130 in tnbc
-
1:43
dr. rugo on the results of the keynote-522 trial in tnbc
-
1:56
dr. schmid on benefit of pembrolizumab in patients with tnbc
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
21:00
precision medicine in metastatic triple negative breast cancer
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
8:32
immunotherapy for triple-negative breast cancer
-
0:51
challenges in the treatment of mtnbc
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
27:45
treatment options for triple-negative breast cancer prof. peter schmid
-
3:05
esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study
-
4:47
optimizing perioperative treatment strategies in tnbc
-
7:15
pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembr...
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
0:59
dr. burris on treatment considerations in tnbc
-
5:49
neoadjuvant treatment for triple-negative breast cancer
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
1:01
the future therapeutic landscape of immunotherapy for mtnbc
-
1:30
begonia: durvalumab combinations in advanced tnbc